-- Continued enrollment in two Phase 2 trials of Adlea for post-operative
pain associated with orthopedic surgeries: one in patients undergoing
total hip replacement surgery, and a second in patients undergoing knee
replacement surgery. These trials are investigating a higher dose of
Adlea that might provide increased efficacy. Anesiva previously
successfully studied a lower dose of Adlea in patients undergoing knee
-- Proceeded with plans to initiate Phase 3 trials of Adlea in
post-surgical pain associated with orthopedic surgeries, including one
trial in patients undergoing bunionectomy surgeries and one trial in
patients undergoing total knee replacement surgeries.
Anesiva announced that Richard P. Powers, vice president and chief financial officer, will resign at the end of the month to pursue other interests, while remaining a consultant to the company. He will be succeeded by Jean-Frederic Viret, Ph.D., who is currently Anesiva's vice president, finance.
"Dick has been a valuable member of the Anesiva senior management team, having served as chief financial officer and leader of successful financing efforts almost since the company's inception. We are grateful for his many contributions and will appreciate the ongoing benefit of his counsel," said Mr. McLaughlin. "We are also pleased that we will have a smooth transition with the promotion of Jean Viret to vice president and chief financial officer. Jean has been a leader in our finance group since 2002, and we are confident that in this new position he will have a significant role in Anesiva's growth."
Jean-Frederic Viret, Ph.D. joined Anesiva in 2002 and was promoted to
vice president, finance in 2006. Prior to Anesiva, Jean was associate
director of finance at Tularik Inc. (now Amg
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved